Oxervate
cenegermin · Dompe' Farmaceutici S.p.A.
ORPHAN AUTHORISED IN THE EUWhat Oxervate is used for
Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Oxervate
- Active substance
- cenegermin
- Disease area
- Keratitis
- Medicine group
- Ophthalmologicals
- ATC code
- S01
- Marketing authorisation holder
- Dompe' Farmaceutici S.p.A.
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Oxervate used for?
Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
What is the active substance in Oxervate?
Oxervate contains cenegermin.
Who makes Oxervate?
The EU marketing authorisation holder is Dompe' Farmaceutici S.p.A..
Is Oxervate an orphan medicine?
Yes. Oxervate is designated an orphan medicine in the EU, for a rare disease (Keratitis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU